TY - JOUR T1 - Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1186/s40425-017-0278-6 VL - 5 IS - 1 SP - 77 AU - Andrew Zloza AU - A. Karolina Palucka AU - Lisa M. Coussens AU - Philip J. Gotwals AU - Mark B. Headley AU - Elizabeth M. Jaffee AU - Amanda W. Lund AU - Arlene H. Sharpe AU - Mario Sznol AU - Derek A. Wainwright AU - Kwok-Kin Wong AU - Marcus W. Bosenberg Y1 - 2017/12/01 UR - http://jitc.bmj.com/content/5/1/77.abstract N2 - Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Society for Immunotherapy of Cancer (SITC) convened a workshop titled, “Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy” as part of the SITC 31st Annual Meeting and Associated Programs on November 10, 2016 in National Harbor, MD. The workshop focused on key issues in optimizing models for cancer immunotherapy research, with discussions on the strengths and weaknesses of current models, approaches to improve the predictive value of mouse models, and advances in cancer modeling that are anticipated in the near future. This full-day program provided an introduction to the most common immunocompetent and humanized models used in cancer immunology and immunotherapy research, and addressed the use of models to evaluate immune-targeting therapies. Here, we summarize the workshop presentations and subsequent panel discussion.Abbreviations:3DThree-dimensionalATCCAmerican Type Culture CollectionCARChimeric antigen receptorCNSCentral nervous systemCSFColony stimulating factorCTLCytotoxic T lymphocyteDCDendritic cell(s)DDRDNA damage responseFDAFood and Drug AdministrationGBMGlioblastoma multiformeGEMMsGenetically engineered mouse modelsGVHDGraft-versus-host diseaseIDO1Indoleamine 2,3-dioxygenase 1LNLymph node(s)MDSCMyeloid-derived suppressor cell(s)NKNatural killer cell(s)OSOverall survivalPBMCPeripheral blood mononuclear cell(s)PD-1Programmed cell death 1PDXPatient-derived xenograftSITCSociety for Immunotherapy of CancerSTINGStimulator of interferon genesTAMTumor-associated macrophage(s)TCRT cell receptor(s)TILTumor infiltrating lymphocyte(s)TMETumor microenvironmentTregRegulatory T cell(s)VEGFRVascular endothelial growth factor receptorWTWild typeYUMMYale University mouse melanoma ER -